Classic Hodgkin Lymphoma in Adolescents and Young Adults.
Kara M KellyJonathan W FriedbergPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hodgkin lymphoma (HL) represents one of the more common cancers occurring in adolescent and young adults (AYAs) age 15-39 years. Despite a generally high cure rate, age-related differences in HL biology and the optimal therapeutic approaches including supportive care and risks for long-term adverse effects in the AYA population remain understudied. After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches. Recently completed and ongoing studies will foster harmonization of risk group definition and trial eligibility criteria across the AYA spectrum, enabling more rapid progress. In addition to treatment approaches, an evolving holistic care approach to AYA HL will result in enhanced understanding of unique challenges, and continued improved short- and long-term outcome for these patients.
Keyphrases
- hodgkin lymphoma
- young adults
- healthcare
- palliative care
- newly diagnosed
- clinical trial
- ejection fraction
- quality improvement
- randomized controlled trial
- prognostic factors
- mental health
- study protocol
- risk assessment
- chronic pain
- combination therapy
- phase ii
- patient reported outcomes
- loop mediated isothermal amplification